The FDA designated Abbott's recall of FreeStyle Libre 3 sensors as the most serious, class I type due to the risk for ...

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

The announcement comes just after Dexcom, another diabetes company, released its own consumer-friendly sensor. Here's what to ...

Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

The US Food and Drug Administration (FDA) has tagged Abbott’s recent recall of its faulty FreeStyle Libre 3 sensors as Class ...

Abbott introduced a revolutionary new device, FreeStyle Navigator, designed to improve the lives of the world’s more than 500 ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

Some better-ranked stocks in the broader medical space are TransMedix Group TMDX, Veracyte VCYT and Boston Scientific BSX. While TransMedix Group and Veracyte currently sport a Zacks Rank #1 (Strong ...

Abbott Diabetes Care, Inc. is recalling its FreeStyle Libre 3 sensors after finding a small number of the sensors may provide incorrect high glucose readings, which, if undetected may pose ...

Ltd. Boston Scientific (Bard® Stent System, Antibacterial Coating Technologies) Abbott Laboratories (Xience® Drug-Eluting ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetesWith a single sensor, the ...